Researchers in Gastroenterology evaluated strategies for preventing avoidable colorectal cancers after colonoscopy. In ...

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of ...

Upadacitinib is potentially safe and effective for patients with moderate to severe atopic dermatitis, irrespective of ...

A key regulatory win could turn this under-the-radar treatment into AbbVie's next billion-dollar success story.

Upadacitinib and deucravacitinib consistently were in the top two across efficacy measures. Among small-molecule drugs, upadacitinib and deucravacitinib demonstrate the best efficacy for treatment ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Upadacitinib combined with topical corticosteroids led to rapid and lasting relief from atopic dermatitis (AD ...

AbbVie (ABBV) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted an opinion recommending the ...

EMA committee recommends approval of AbbVie’s upadacitinib to treat adults with giant cell arteritis: North Chicago, Illinois Monday, March 3, 2025, 15:00 Hrs [IST] AbbVie annou ...

(RTTNews) - AbbVie (ABBV) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of upadacitinib ...

In the first one, Nicole Garcia, BA, of the University of California San Francisco (UCSF) reported that, during 2 years of treatment with tofacitinib (Xeljanz) or upadacitinib (Rinvoq), no major ...

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of AbbVie's upadacitinib (Rinvoq) to treat adults with giant cell arteritis (GCA).

AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of upadacitinib ...